Welcome to our dedicated page for Nexalin Tech news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology, Inc. (Nasdaq: NXL) is a medical device company that develops non-invasive, frequency-based neurostimulation products aimed at mental health and neurological conditions. The Nexalin news feed on Stock Titan highlights company announcements, clinical study results, regulatory milestones, and capital markets updates related to its Deep Intracranial Frequency Stimulation (DIFS™) technology.
Recent news releases describe peer-reviewed studies in Alzheimer’s disease, dementia, Attention Deficit Hyperactivity Disorder (ADHD), and a case involving gambling disorder with alcohol use disorder, where Nexalin’s 15 milliamp DIFS™ devices were associated with cognitive improvements, changes in brain network activity, and favorable safety profiles. Other updates cover regulatory approvals for the Gen-2 SYNC console in markets such as Israel, China, Brazil, and Oman, as well as U.S. FDA Q-Submission interactions for Alzheimer’s and dementia programs.
Investors and observers can use this page to follow Nexalin’s progress in advancing its Gen-2 and Gen-3 platforms, including the Gen-2 SYNC console and the Gen-3 HALO™ Clarity headset, along with developments in areas like traumatic brain injury research and international distribution agreements. News items also include information on investor events, such as webinars and conference participation, and SEC-related disclosures that may influence the company’s strategic and financial position.
By reviewing the NXL news stream, readers gain insight into how Nexalin’s DIFS™ technology is being evaluated in clinical settings, how regulators are engaging with its devices, and how the company is positioning its non-invasive, drug-free neuromodulation platform within the broader mental health and neurodegenerative disease landscape.
Nexalin (Nasdaq:NXL) launched NeuroCare®, an AI-designed virtual clinic integrated with its new Gen-3 HALO™ headset to deliver home-based Deep Intracranial Frequency Stimulation (DIFS™).
The platform, deployed initially with UC San Diego, supports remote physician monitoring, subscription billing, and clinical trial enrollment for Alzheimer’s, mood disorders, TBI and PTSD.
Nexalin (Nasdaq: NXL) highlighted a growing peer-reviewed neuroimaging literature supporting its Deep Intracranial Frequency Stimulation (DIFS™) as a non-invasive approach that modulates deep brain networks across mood, military, and memory indications.
Key studies include a randomized, double-blind, sham-controlled trial showing objective gamma‑frequency normalization via MEG/EEG and multiple fMRI/PET reports linking network changes to clinical improvement.
Nexalin Technology (Nasdaq: NXL) received a Nasdaq notification dated January 21, 2026 stating it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after 30 consecutive business days below the $1.00 bid threshold. The company has been granted 180 calendar days, until July 20, 2026, to regain compliance by achieving a closing bid of at least $1.00 for a minimum of 10 consecutive trading days. Shares will continue to trade uninterrupted under ticker NXL. The company said it will monitor the bid price and is considering measures to improve its financial position; it is not considering a reverse stock split at this time.
Nexalin Technology (Nasdaq: NXL) announced a peer‑reviewed, randomized double‑blind sham‑controlled trial published in Molecular Psychiatry showing four weeks of its non‑invasive DIFS™ neurostimulation improved attention and normalized brain activity in adults with ADHD.
In 56 adults, active treatment produced a 10.1‑point average improvement on the Adult ADHD Self‑Report Scale versus 5.5‑points for sham (4.6‑point separation, p < 0.001), plus MEG/EEG evidence of reduced excessive gamma activity and restored network communication. Treatment was well tolerated with no serious adverse events reported.
Nexalin Technology (NASDAQ: NXL) completed a substantive FDA Q-Submission meeting for its Gen-2 SYNC™ neurostimulation console targeting mild-to-moderate Alzheimer’s disease on December 3, 2025. The FDA provided a clear framework for Nexalin’s planned U.S. Pilot Study and discussed a potential De Novo classification pathway.
FDA and Nexalin aligned on pilot and pivotal trial design elements, patient population, dosing paradigm, statistical plan, and primary/secondary endpoints including cognitive tests, PET, blood biomarkers, and functional imaging. Company will use feedback for its U.S. IDE submission.
Nexalin Technology (Nasdaq: NXL) invites investors to a live webinar on December 4, 2025 at 4:15 p.m. ET hosted by RedChip Companies.
CEO Mark White will discuss Nexalin’s proprietary non-invasive Deep Intracranial Frequency Stimulation (DIFS™), recent clinical collaborations including UC San Diego, the Gen-3 HALO™ Clarity headset, and a Virtual Clinic model for scalable at-home treatment. The company says it has secured regulatory approvals internationally while pursuing U.S. expansion and targets the $537 billion mental health market. Management will highlight patented technology, real-time AI-driven patient monitoring, and global footprint growth, followed by a live Q&A. Registration is free at the RedChip webinar page and questions can be pre-submitted to NXL@redchip.com.
Nexalin Technology (Nasdaq: NXL) reported a peer-reviewed case report in The American Journal on Addictions showing promising results using its 15 mA neurostimulation device to treat gambling disorder comorbid with alcohol use disorder.
In a single patient treated at Shanghai Mental Health Center, 20 outpatient sessions over 10 days (15 mA at 77.5 Hz for 40 minutes each) produced complete abstinence from gambling and alcohol, improved cognitive control, and no adverse effects during a three-month follow-up. The study (ClinicalTrials.gov NCT06195995) received ethics approval. The device is approved in China for depression and insomnia. Authors recommend larger controlled trials to confirm findings.
Nexalin Technology (Nasdaq: NXL) announced an exclusive distribution agreement with Carmi Masha Technologies Ltd. to market and sell Nexalin’s Gen-2 SYNC 15 mA non-invasive neurostimulation console in Israel.
The agreement follows regulatory approval by the Israeli Ministry of Health authorizing commercial sale for indications including insomnia, depression, and anxiety. Carmi Masha will handle importation, registration, sales, marketing, clinical education, and distribution to hospitals, clinics, and private centers.
The companies also plan to explore future clinical applications for PTSD, TBI, Alzheimer’s, and dementia as part of ongoing global clinical initiatives.
Nexalin Technology (Nasdaq: NXL) announced that the U.S. Food and Drug Administration accepted its Q-Submission for the Gen-2 SYNC console for treatment of Alzheimer’s disease and dementia on November 5, 2025.
The acceptance schedules a regulatory meeting later in 2025 to discuss clinical trial design, endpoints, statistical plans and the regulatory pathway toward a potential U.S. Investigational Device Exemption (IDE).
Company-reported supportive signals include encouraging internal data, published studies showing improved cognitive performance, no serious adverse events across international use, and EEG/qEEG evidence of waveform-induced neural connectivity changes for dementia-related conditions.
Nexalin Technology (Nasdaq: NXL) announced regulatory approval from the Israeli Ministry of Health to sell its Gen-2 SYNC 15 mA neurostimulation DIFS™ device in Israel on October 30, 2025. The company said the clearance enables commercial launch discussions with regional distribution partners and strengthens global credibility after prior approvals in China, Brazil, and Oman. The approval supports Nexalin’s strategy to expand its non‑invasive mental health therapy platform across the region.